<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37638017</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy.</ArticleTitle><Pagination><StartPage>1128754</StartPage><MedlinePgn>1128754</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1128754</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1128754</ELocationID><Abstract><AbstractText>Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease that results in significant damage and often needs more aggressive treatment. Compared to adult-onset SLE, cSLE has a stronger genetic background and more prevalent elevated type I Interferon expression. The management of cSLE is more challenging because the disease itself and treatment can affect physical, psychological and emotional growth and development. High dose oral glucocorticoid (GC) has become the rule for treating moderate to severe cSLE activity. However, GC-related side effects and potential toxicities are problems that cannot be ignored. Recent studies have suggested that GC pulse therapy can achieve disease remission rapidly and reduce GC-related side effects with a reduction in oral prednisone doses. This article reviews characteristics, including pathogenesis and manifestations of cSLE, and summarized the existing evidence on GC therapy, especially on GC pulse therapy in cSLE, followed by our proposal for GC therapy according to the clinical effects and pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Pan, Liu, Liu, Guo, Punaro and Yang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Immunology and Allergy, The First Hospital, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jinxiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Immunology and Allergy, The First Hospital, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Congcong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Immunology and Allergy, The First Hospital, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Lishuang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Immunology and Allergy, The First Hospital, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Punaro</LastName><ForeName>Marilynn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology, Texas Scottish Rite Hospital for Children, Houston, TX, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Rheumatology, Children's Medical Center of Dallas, Dallas, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Sirui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Immunology and Allergy, The First Hospital, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">childhood-onset systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">genetic factors</Keyword><Keyword MajorTopicYN="N">glucocorticoids</Keyword><Keyword MajorTopicYN="N">intravenous methylprednisolone pulse therapy</Keyword><Keyword MajorTopicYN="N">type I interferon</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>4</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37638017</ArticleId><ArticleId IdType="pmc">PMC10448525</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1128754</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr (2020) 16(1):19&#x2013;30. doi: 10.1007/s12519-019-00229-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-019-00229-3</ArticleId><ArticleId IdType="pmc">PMC7040062</ArticleId><ArticleId IdType="pubmed">30796732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamada MM, Jia Y, Wu X. Macrophage polarization and plasticity in systemic lupus erythematosus. Front Immunol (2021) 12:734008. doi: 10.3389/fimmu.2021.734008</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.734008</ArticleId><ArticleId IdType="pmc">PMC8721097</ArticleId><ArticleId IdType="pubmed">34987500</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken) (2012) 64(12):1787&#x2013;93. doi: 10.1002/acr.21757</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21757</ArticleId><ArticleId IdType="pmc">PMC3463746</ArticleId><ArticleId IdType="pubmed">22730317</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Garf K, El-Garf A, Gheith R, Badran S, Salah S, Marzouk H, et al. . A comparative study between the disease characteristics in adult-onset and childhood-onset systemic lupus erythematosus in Egyptian patients attending a large university hospital. Lupus (2021) 30(2):211&#x2013;8. doi: 10.1177/0961203320972778</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320972778</ArticleId><ArticleId IdType="pubmed">33175664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright TB, Punaro M. Paediatric systemic lupus erythematosus: insights from translational research. Rheumatol (Oxf) (2017) 56(suppl_1):i24&#x2013;31. doi: 10.1093/rheumatology/kew447</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew447</ArticleId><ArticleId IdType="pubmed">28375454</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatemi A, Matinfar M, Smiley A. Childhood versus adult-onset systemic lupus erythematosus: long-term outcome and predictors of mortality. Clin Rheumatol (2017) 36(2):343&#x2013;50. doi: 10.1007/s10067-016-3509-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-016-3509-1</ArticleId><ArticleId IdType="pubmed">28012055</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorot FJ, Islab&#xe3;o AG, Pereira RM, Terreri MT, Saad-Magalh&#xe3;es C, Novak GV, et al. . Disease presentation of 1312 childhood-onset systemic lupus erythematosus: influence of ethnicity. Clin Rheumatol (2019) 38(10):2857&#x2013;63. doi: 10.1007/s10067-019-04631-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-019-04631-0</ArticleId><ArticleId IdType="pubmed">31209708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatol (Oxf) (2020) 59(Suppl5):v69&#x2013;81. doi: 10.1093/rheumatology/keaa403</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa403</ArticleId><ArticleId IdType="pmc">PMC7719039</ArticleId><ArticleId IdType="pubmed">33280011</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Ugarte A, Ruiz-Arruza I, Khamashta M. Seventy years after Hench&#x2019;s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus (2020) 29(10):1155&#x2013;67. doi: 10.1177/0961203320930099</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320930099</ArticleId><ArticleId IdType="pubmed">32539657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatol (Oxf) (2014) 53(8):1470&#x2013;6. doi: 10.1093/rheumatology/keu148</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu148</ArticleId><ArticleId IdType="pubmed">24681836</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Kamphuis S, Beyene J, Wither J, Harley JB, Blanco I, et al. . Relationship between genetic risk and age of diagnosis in systemic lupus erythematosus. J Rheumatol (2021) 48(6):852&#x2013;8. doi: 10.3899/jrheum.200002</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200002</ArticleId><ArticleId IdType="pubmed">33060314</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirkaya E, Zhou Q, Smith CK, Ombrello MJ, Deuitch N, Tsai WL, et al. . Brief report: deficiency of complement 1r subcomponent in early-onset systemic lupus erythematosus: the role of disease-modifying alleles in a monogenic disease. Arthritis Rheumatol (2017) 69(9):1832&#x2013;9. doi: 10.1002/art.40158</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40158</ArticleId><ArticleId IdType="pmc">PMC5609811</ArticleId><ArticleId IdType="pubmed">28544690</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirkaya E, Sahin S, Romano M, Zhou Q, Aksentijevich I. New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: monogenic lupus and beyond. J Clin Med (2020) 9(3):712. doi: 10.3390/jcm9030712</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030712</ArticleId><ArticleId IdType="pmc">PMC7141186</ArticleId><ArticleId IdType="pubmed">32151092</ArticleId></ArticleIdList></Reference><Reference><Citation>Omarjee O, Picard C, Frachette C, Moreews M, Rieux-Laucat F, Soulas-Sprauel P, et al. . Monogenic lupus: Dissecting heterogeneity. Autoimmun Rev (2019) 18(10):102361. doi: 10.1016/j.autrev.2019.102361</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.102361</ArticleId><ArticleId IdType="pubmed">31401343</ArticleId></ArticleIdList></Reference><Reference><Citation>An J, Briggs TA, Dumax-Vorzet A, Alarc&#xf3;n-Riquelme ME, Belot A, Beresford M, et al. . Tartrate-resistant acid phosphatase deficiency in the predisposition to systemic lupus erythematosus. Arthritis Rheumatol (2017) 69(1):131&#x2013;42. doi: 10.1002/art.39810</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39810</ArticleId><ArticleId IdType="pubmed">27390188</ArticleId></ArticleIdList></Reference><Reference><Citation>Alperin JM, Ortiz-Fern&#xe1;ndez L, Sawalha AH. Monogenic lupus: A developing paradigm of disease. Front Immunol (2018) 9:2496. doi: 10.3389/fimmu.2018.02496</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02496</ArticleId><ArticleId IdType="pmc">PMC6232876</ArticleId><ArticleId IdType="pubmed">30459768</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol (2012) 8(8):458&#x2013;68. doi: 10.1038/nrrheum.2012.75</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2012.75</ArticleId><ArticleId IdType="pubmed">22664835</ArticleId></ArticleIdList></Reference><Reference><Citation>Belot A, Kasher PR, Trotter EW, Foray AP, Debaud AL, Rice GI, et al. . Protein kinase c&#x3b4; deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum (2013) 65(8):2161&#x2013;71. doi: 10.1002/art.38008</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38008</ArticleId><ArticleId IdType="pmc">PMC4066615</ArticleId><ArticleId IdType="pubmed">23666743</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter JE, Lo MS, Kis-Toth K, Tirosh I, Frugoni F, Lee YN, et al. . Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis. J Allergy Clin Immunol (2015) 135(1):272&#x2013;3. doi: 10.1016/j.jaci.2014.07.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2014.07.063</ArticleId><ArticleId IdType="pmc">PMC4289116</ArticleId><ArticleId IdType="pubmed">25312763</ArticleId></ArticleIdList></Reference><Reference><Citation>Charras A, Smith E, Hedrich CM. Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep (2021) 23(3):20. doi: 10.1007/s11926-021-00985-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-00985-0</ArticleId><ArticleId IdType="pmc">PMC7875946</ArticleId><ArticleId IdType="pubmed">33569643</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Tsao BP. Updates in lupus genetics. Curr Rheumatol Rep (2017) 19(11):68. doi: 10.1007/s11926-017-0695-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-017-0695-z</ArticleId><ArticleId IdType="pubmed">28983873</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb R, Kelly JA, Somers EC, Hughes T, Kaufman KM, Sanchez E, et al. . Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis (2011) 70(1):151&#x2013;6. doi: 10.1136/ard.2010.141697</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.141697</ArticleId><ArticleId IdType="pmc">PMC3034281</ArticleId><ArticleId IdType="pubmed">20881011</ArticleId></ArticleIdList></Reference><Reference><Citation>Joo YB, Lim J, Tsao BP, Nath SK, Kim K, Bae SC. Genetic variants in systemic lupus erythematosus susceptibility loci, XKR6 and GLT1D1 are associated with childhood-onset SLE in a Korean cohort. Sci Rep (2018) 8(1):9962. doi: 10.1038/s41598-018-28128-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-28128-z</ArticleId><ArticleId IdType="pmc">PMC6028392</ArticleId><ArticleId IdType="pubmed">29967481</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber D, Cao J, Dominguez D, Gladman DD, Levy DM, Ng L, et al. . Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. Rheumatol (Oxf) (2020) 59(1):90&#x2013;8. doi: 10.1093/rheumatology/kez220</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez220</ArticleId><ArticleId IdType="pubmed">31236574</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang SH, Stanley M, Vinuesa CG. Rare genetic variants in systemic autoimmunity. Immunol Cell Biol (2020) 98(6):490&#x2013;9. doi: 10.1111/imcb.12339</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12339</ArticleId><ArticleId IdType="pubmed">32315078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullabhatla V, Roberts AL, Lewis MJ, Mauro D, Morris DL, Odhams CA, et al. . De nov mutations implicate novel genes in systemic lupus erythematosus. Hum Mol Genet (2018) 27(3):421&#x2013;9. doi: 10.1093/hmg/ddx407</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx407</ArticleId><ArticleId IdType="pmc">PMC5886157</ArticleId><ArticleId IdType="pubmed">29177435</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Gallman AE, Xie C, Shen Q, Ma J, Wolfreys FD, et al. . P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance. J Exp Med (2022) 219(1):e20211004. doi: 10.1084/jem.20211004</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211004</ArticleId><ArticleId IdType="pmc">PMC8669517</ArticleId><ArticleId IdType="pubmed">34889940</ArticleId></ArticleIdList></Reference><Reference><Citation>Farias FHG, Dahlqvist J, Kozyrev SV, Leonard D, Wilbe M, Abramov SN, et al. . A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. Eur J Hum Genet (2019) 27(3):432&#x2013;41. doi: 10.1038/s41431-018-0297-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0297-x</ArticleId><ArticleId IdType="pmc">PMC6460566</ArticleId><ArticleId IdType="pubmed">30459414</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Zhao J, Sun Q, Xu X, Wang L, Liu T, et al. . Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus. Ann Rheum Dis (2022) 81(12):1712&#x2013;21. doi: 10.1136/ard-2022-222795</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222795</ArticleId><ArticleId IdType="pmc">PMC10394691</ArticleId><ArticleId IdType="pubmed">35977808</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras-Cubas C, Garc&#xed;a-Ortiz H, Vel&#xe1;zquez-Cruz R, Barajas-Olmos F, Baca P, Mart&#xed;nez-Hern&#xe1;ndez A, et al. . Catalytically impaired TYK2 variants are protective against childhood- and adult-onset systemic lupus erythematosus in Mexicans. Sci Rep (2019) 9(1):12165. doi: 10.1038/s41598-019-48451-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48451-3</ArticleId><ArticleId IdType="pmc">PMC6704113</ArticleId><ArticleId IdType="pubmed">31434951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisiel BM, Kosinska J, Wierzbowska M, Rutkowska-Sak L, Musiej-Nowakowska E, Wudarski M, et al. . Differential association of juvenile and adult systemic lupus erythematosus with genetic variants of oestrogen receptors alpha and beta. Lupus (2011) 20(1):85&#x2013;9. doi: 10.1177/0961203310381514</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310381514</ArticleId><ArticleId IdType="pubmed">20961965</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmaninejad A, Mahmoudi M, Aslani S, Poursani S, Ziaee V, Rezaei N. Association of STAT4 gene single nucleotide polymorphisms with Iranian juvenile-onset systemic lupus erythematosus patients. Turk J Pediatr (2017) 59(2):144&#x2013;9. doi: 10.24953/turkjped.2017.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.24953/turkjped.2017.02.005</ArticleId><ArticleId IdType="pubmed">29276866</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoudi M, Aslani S, Hamzeh E, Ziaee V, Poursani S, Nicknam MH, et al. . Association study of MECP2 gene single nucleotide polymorphisms in juvenile-onset systemic lupus erythematosus patients from Iran. Fetal Pediatr Pathol (2017) 36(6):423&#x2013;31. doi: 10.1080/15513815.2017.1367871</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15513815.2017.1367871</ArticleId><ArticleId IdType="pubmed">29199882</ArticleId></ArticleIdList></Reference><Reference><Citation>Vel&#xe1;zquez-Cruz R, Orozco L, Espinosa-Rosales F, Carre&#xf1;o-Manjarrez R, Sol&#xed;s-Vallejo E, L&#xf3;pez-Lara ND, et al. . Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. Eur J Hum Genet (2007) 15(3):336&#x2013;41. doi: 10.1038/sj.ejhg.5201767</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejhg.5201767</ArticleId><ArticleId IdType="pubmed">17228327</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosaad YM, Hammad A, AlHarrass MF, Sallam R, Shouma A, Hammad E, et al. . ARID5B rs10821936 and rs10994982 gene polymorphism and susceptibility to juvenile systemic lupus erythematosus and lupus nephritis. Lupus (2021) 30(8):1226&#x2013;32. doi: 10.1177/09612033211010338</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211010338</ArticleId><ArticleId IdType="pubmed">33888010</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira KM, Faria AG, Liphaus BL, Jesus AA, Silva CA, Carneiro-Sampaio M, et al. . Low C4, C4A and C4B gene copy numbers are stronger risk factors for juvenile-onset than for adult-onset systemic lupus erythematosus. Rheumatol (Oxf) (2016) 55(5):869&#x2013;73. doi: 10.1093/rheumatology/kev436</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev436</ArticleId><ArticleId IdType="pubmed">26800705</ArticleId></ArticleIdList></Reference><Reference><Citation>Coit P, Roopnarinesingh X, Ortiz-Fern&#xe1;ndez L, McKinnon-Maksimowicz K, Lewis EE, Merrill JT, et al. . Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature. Ann Rheum Dis (2022) 81(10):1428&#x2013;37. doi: 10.1136/annrheumdis-2022-222656</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222656</ArticleId><ArticleId IdType="pmc">PMC10259175</ArticleId><ArticleId IdType="pubmed">35710306</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Su G, Wang Z, Shangguan S, Cui X, Zhu J, et al. . Hypomethylation of long interspersed nucleotide element-1 in peripheral mononuclear cells of juvenile systemic lupus erythematosus patients in China. Int J Rheum Dis (2014) 17(3):280&#x2013;90. doi: 10.1111/1756-185X.12239</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12239</ArticleId><ArticleId IdType="pubmed">24330152</ArticleId></ArticleIdList></Reference><Reference><Citation>von Knethen A, Heinicke U, Weigert A, Zacharowski K, Br&#xfc;ne B. Histone deacetylation inhibitors as modulators of regulatory T cells. Int J Mol Sci (2020) 21(7):2356. doi: 10.3390/ijms21072356</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21072356</ArticleId><ArticleId IdType="pmc">PMC7177531</ArticleId><ArticleId IdType="pubmed">32235291</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Hernandez J, Martinez-Arroyo O, Ortega A, Galera M, Solis-Salguero MA, Chaves FJ, et al. . Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis. J Nephrol (2021) 34(4):1157&#x2013;67. doi: 10.1007/s40620-020-00832-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-020-00832-y</ArticleId><ArticleId IdType="pubmed">32803682</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Tang C, Chen D, Li F, Huang M, Ye J, et al. . miR-98 modulates cytokine production from human PBMCs in systemic lupus erythematosus by targeting IL-6 mRNA. J Immunol Res (2019) 2019:9827574. doi: 10.1155/2019/9827574</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/9827574</ArticleId><ArticleId IdType="pmc">PMC6914974</ArticleId><ArticleId IdType="pubmed">31886314</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Wang L, Shi Y, Deng Y, Oates JC, Kamen DL, et al. . Up-regulated interleukin-10 induced by E2F transcription factor 2-microRNA-17-5p circuitry in extrafollicular effector B cells contributes to autoantibody production in systemic lupus erythematosus. Arthritis Rheumatol (2022) 74(3):496&#x2013;507. doi: 10.1002/art.41987</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41987</ArticleId><ArticleId IdType="pmc">PMC10403296</ArticleId><ArticleId IdType="pubmed">34569195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Guo Y, Sun Y, Chang L, Wang X. Inhibition of microRNA-448 suppresses CD4(+) T cell inflammatory activation via up-regulating suppressor of cytokine signaling 5 in systemic lupus erythematosus. Biochem Biophys Res Commun (2022) 596:88&#x2013;96. doi: 10.1016/j.bbrc.2022.01.097</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2022.01.097</ArticleId><ArticleId IdType="pubmed">35121374</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Guo Q, Wu C, Sterlin D, Goswami S, Zhang Y, et al. . Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients. Cell Mol Immunol (2019) 16(4):367&#x2013;79. doi: 10.1038/s41423-018-0010-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-018-0010-6</ArticleId><ArticleId IdType="pmc">PMC6461980</ArticleId><ArticleId IdType="pubmed">29563616</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallucci S, Meka S, Gamero AM. AbnorMalities of the type I interferon signaling pathway in lupus autoimmunity. Cytokine (2021) 146:155633. doi: 10.1016/j.cyto.2021.155633</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155633</ArticleId><ArticleId IdType="pmc">PMC8475157</ArticleId><ArticleId IdType="pubmed">34340046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 197(6):711&#x2013;23. doi: 10.1084/jem.20021553</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021553</ArticleId><ArticleId IdType="pmc">PMC2193846</ArticleId><ArticleId IdType="pubmed">12642603</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA (2003) 100(5):2610&#x2013;5. doi: 10.1073/pnas.0337679100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo S, Wang Y, Zhao M, Lu Q. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus. Int Immunopharmacol (2016) 40:542&#x2013;9. doi: 10.1016/j.intimp.2016.10.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2016.10.012</ArticleId><ArticleId IdType="pubmed">27769023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y, Park J, Takamatsu H, Konaka H, Aoki W, Aburaya S, et al. . Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. Ann Rheum Dis (2018) 77(10):1507&#x2013;15. doi: 10.1136/annrheumdis-2018-212988</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-212988</ArticleId><ArticleId IdType="pmc">PMC6161667</ArticleId><ArticleId IdType="pubmed">29945921</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol (2007) 7(5):353&#x2013;64. doi: 10.1038/nri2079</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2079</ArticleId><ArticleId IdType="pubmed">17457343</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. . Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med (2011) 3(73):73ra20. doi: 10.1126/scitranslmed.3001201</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001201</ArticleId><ArticleId IdType="pmc">PMC3143837</ArticleId><ArticleId IdType="pubmed">21389264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyuan IT, Tzeng HT, Chen JY. Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells (2019) 8(9):963. doi: 10.3390/cells8090963</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8090963</ArticleId><ArticleId IdType="pmc">PMC6769759</ArticleId><ArticleId IdType="pubmed">31450787</ArticleId></ArticleIdList></Reference><Reference><Citation>Eloranta ML, R&#xf6;nnblom L. Cause and consequences of the activated type I interferon system in SLE. J Mol Med (Berl) (2016) 94(10):1103&#x2013;10. doi: 10.1007/s00109-016-1421-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-016-1421-4</ArticleId><ArticleId IdType="pmc">PMC5052287</ArticleId><ArticleId IdType="pubmed">27094810</ArticleId></ArticleIdList></Reference><Reference><Citation>Osokine I, Snell LM, Cunningham CR, Yamada DH, Wilson EB, Elsaesser HJ, et al. . Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection. Proc Natl Acad Sci USA (2014) 111(20):7409&#x2013;14. doi: 10.1073/pnas.1401662111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1401662111</ArticleId><ArticleId IdType="pmc">PMC4034239</ArticleId><ArticleId IdType="pubmed">24799699</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg N, Berggren O, Leonard D, Weber G, Bryceson YT, Alm GV, et al. . IFN-&#x3b1; production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes is promoted by NK cells via MIP-1&#x3b2; and LFA-1. J Immunol (2011) 186(9):5085&#x2013;94. doi: 10.4049/jimmunol.1003349</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1003349</ArticleId><ArticleId IdType="pubmed">21430220</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley A, Thorbinson C, Beresford MW. Expression of Toll-like receptors and their detection of nuclear self-antigen leading to immune activation in JSLE. Rheumatol (Oxf) (2012) 51(5):824&#x2013;32. doi: 10.1093/rheumatology/ker400</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker400</ArticleId><ArticleId IdType="pubmed">22253024</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis (2015) 18(2):182&#x2013;91. doi: 10.1111/1756-185X.12419</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12419</ArticleId><ArticleId IdType="pubmed">24965742</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundhun PK, Kumari A, Huang F. Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: A systematic review and meta-analysis. Med (Baltimore) (2017) 96(37):e8086. doi: 10.1097/MD.0000000000008086</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000008086</ArticleId><ArticleId IdType="pmc">PMC5604682</ArticleId><ArticleId IdType="pubmed">28906413</ArticleId></ArticleIdList></Reference><Reference><Citation>das Chagas Medeiros MM, Bezerra MC, Braga FN, da Justa Feij&#xe3;o MR, Gois AC, Rebou&#xe7;as VC, et al. . Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): comparison between childhood-onset, adult-onset, and late-onset SLE. Lupus (2016) 25(4):355&#x2013;63. doi: 10.1177/0961203315606983</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315606983</ArticleId><ArticleId IdType="pubmed">26405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassi RH, Hendler JV, Piccoli GF, Gasparin AA, da Silva Chakr RM, Brenol JC, et al. . Age of onset influences on clinical and laboratory profile of patients with systemic lupus erythematosus. Clin Rheumatol (2017) 36(1):89&#x2013;95. doi: 10.1007/s10067-016-3478-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-016-3478-4</ArticleId><ArticleId IdType="pubmed">27858177</ArticleId></ArticleIdList></Reference><Reference><Citation>Kliegman RM, Shah SS, Tasker RC, Wilson KM, Behrman RE. Nelson Textbook of Pediatrics. (Beijing: World Book Inc.) (2017).</Citation></Reference><Reference><Citation>Bortolini MFF, Pereira VP, Gomes Dos Santos TA, Nisihara R, Skare TL. Systemic lupus erythematosus in children and adults: A retrospective study in Brazilian patients. Lupus (2021) 30(7):1197&#x2013;202. doi: 10.1177/09612033211010330</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211010330</ArticleId><ArticleId IdType="pubmed">33858265</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng JB, Ni JD, Yao X, Pan HF, Li XP, Xu JH, et al. . Gender and age influence on clinical and laboratory features in Chinese patients with systemic lupus erythematosus: 1,790 cases. Rheumatol Int (2010) 30(8):1017&#x2013;23. doi: 10.1007/s00296-009-1087-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-009-1087-0</ArticleId><ArticleId IdType="pubmed">19701756</ArticleId></ArticleIdList></Reference><Reference><Citation>Carre&#xf1;o L, L&#xf3;pez-Longo FJ, Monteagudo I, Rodr&#xed;guez-Mahou M, Bascones M, Gonz&#xe1;lez CM, et al. . Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus (1999) 8(4):287&#x2013;92. doi: 10.1191/096120399678847786</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399678847786</ArticleId><ArticleId IdType="pubmed">10413207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Levy DM, Silverman ED, Hitchon C, Bernatsky S, Pineau C, et al. . A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. Rheumatol (Oxf) (2019). doi: 10.1093/rheumatology/kez006</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez006</ArticleId><ArticleId IdType="pubmed">30805629</ArticleId></ArticleIdList></Reference><Reference><Citation>Gormezano NW, Kern D, Pereira OL, Esteves GC, Sallum AM, Aikawa NE, et al. . Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: differences between pediatric and adult patients. Lupus (2017) 26(4):426&#x2013;30. doi: 10.1177/0961203316676379</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316676379</ArticleId><ArticleId IdType="pubmed">27821514</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa S, Gon&#xe7;alves MJ, In&#xea;s LS, Eug&#xe9;nio G, Jesus D, Fernandes S, et al. . Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register. Rheumatol Int (2016) 36(7):955&#x2013;60. doi: 10.1007/s00296-016-3450-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-016-3450-2</ArticleId><ArticleId IdType="pubmed">26979603</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral B, Murphy G, Ioannou Y, Isenberg DA. A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. Rheumatol (Oxf) (2014) 53(6):1130&#x2013;5. doi: 10.1093/rheumatology/ket488</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket488</ArticleId><ArticleId IdType="pubmed">24505121</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato VA, Marques ID, Goldenstein PT, Carmo LP, Jorge LB, Titan SM, et al. . Lupus nephritis is more severe in children and adolescents than in older adults. Lupus (2012) 21(9):978&#x2013;83. doi: 10.1177/0961203312443421</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312443421</ArticleId><ArticleId IdType="pubmed">22451604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina R, Brunner HI. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther (2013) 15(4):218. doi: 10.1186/ar4256</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4256</ArticleId><ArticleId IdType="pmc">PMC3978647</ArticleId><ArticleId IdType="pubmed">23998441</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos FPST, Nascimento BR, Calderaro DC, Ferreira GA, Correa H. Neuropsychiatric syndromes in childhood-onset systemic lupus erythematosus: A systematic review and meta-analysis. J Clin Rheumatol (2021) 27(5):206&#x2013;14. doi: 10.1097/RHU.0000000000001029</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001029</ArticleId><ArticleId IdType="pubmed">31022053</ArticleId></ArticleIdList></Reference><Reference><Citation>Islab&#xe3;o AG, Mota LMH, Ribeiro MCM, Arabi TM, Cividatti GN, Queiroz LB, et al. . Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients. Autoimmun Rev (2020) 19(12):102693. doi: 10.1016/j.autrev.2020.102693</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102693</ArticleId><ArticleId IdType="pubmed">33164791</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Chalhoub NE, Sherwin CM, Li C, Brunner HI. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum (2019) 49(2):251&#x2013;9. doi: 10.1016/j.semarthrit.2019.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.03.010</ArticleId><ArticleId IdType="pmc">PMC6744986</ArticleId><ArticleId IdType="pubmed">30987856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kifer N, Sestan M, Frkovic M, Kifer D, Kozmar A, Padjen I, et al. . 2019 ACR/EULAR classification criteria and therapy in predicting organ damage accrual in patients with childhood-onset systemic lupus erythematosus: A retrospective study over the last 29 years. Lupus (2022) 31(7):828&#x2013;36. doi: 10.1177/09612033221094707</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221094707</ArticleId><ArticleId IdType="pubmed">35410557</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, et al. . Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis (2002) 61(8):718&#x2013;22. doi: 10.1136/ard.61.8.718</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.61.8.718</ArticleId><ArticleId IdType="pmc">PMC1754188</ArticleId><ArticleId IdType="pubmed">12117678</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M, Floris A, Sebastiani GD, Prevete I, Iannone F, Coladonato L, et al. . Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. Rheumatol (Oxf) (2020) 59(9):2272&#x2013;81. doi: 10.1093/rheumatology/kez584</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez584</ArticleId><ArticleId IdType="pubmed">31840179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids&#x2013;new mechanisms for old drugs. N Engl J Med (2005) 353(16):1711&#x2013;23. doi: 10.1056/NEJMra050541</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra050541</ArticleId><ArticleId IdType="pubmed">16236742</ArticleId></ArticleIdList></Reference><Reference><Citation>Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci (2019) 40(1):38&#x2013;49. doi: 10.1016/j.tips.2018.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2018.11.002</ArticleId><ArticleId IdType="pmc">PMC7106476</ArticleId><ArticleId IdType="pubmed">30497693</ArticleId></ArticleIdList></Reference><Reference><Citation>Strehl C, Buttgereit F. Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. Ann N Y Acad Sci (2014) 1318:1&#x2013;6. doi: 10.1111/nyas.12364</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12364</ArticleId><ArticleId IdType="pubmed">24611742</ArticleId></ArticleIdList></Reference><Reference><Citation>Brien TG. Human corticosteroid binding globulin. Clin Endocrinol (Oxf) (1981) 14(2):193&#x2013;212. doi: 10.1111/j.1365-2265.1981.tb00616.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.1981.tb00616.x</ArticleId><ArticleId IdType="pubmed">7021007</ArticleId></ArticleIdList></Reference><Reference><Citation>Czock D, Keller F, Rasche FM, H&#xe4;ussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet (2005) 44(1):61&#x2013;98. doi: 10.2165/00003088-200544010-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200544010-00003</ArticleId><ArticleId IdType="pubmed">15634032</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf3;th GG, Westerlaken BO, Eilders M, Laseur M, Jonkman MF, Uges DR. Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus. Ann Pharmacother (2002) 36(6):1108&#x2013;9. doi: 10.1345/aph.1A047</Citation><ArticleIdList><ArticleId IdType="doi">10.1345/aph.1A047</ArticleId><ArticleId IdType="pubmed">12058710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S, Kusunoki Y, Oka T, Ito Y, Okuno A, Yoshioka H. Pharmacokinetics of high-dose methylprednisolone in children. Dev Pharmacol Ther (1992) 19(2-3):99&#x2013;105. doi: 10.1159/000457470</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000457470</ArticleId><ArticleId IdType="pubmed">1340442</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, et al. . TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature (2010) 465(7300):937&#x2013;41. doi: 10.1038/nature09102</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09102</ArticleId><ArticleId IdType="pmc">PMC2964153</ArticleId><ArticleId IdType="pubmed">20559388</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, Hoi A, Nikpour M, Morand EF. Independent association of glucocorticoids with damage accrual in SLE. Lupus Sci Med (2016) 3(1):e000157. doi: 10.1136/lupus-2016-000157</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000157</ArticleId><ArticleId IdType="pmc">PMC5133410</ArticleId><ArticleId IdType="pubmed">27933196</ArticleId></ArticleIdList></Reference><Reference><Citation>Jongvilaikasem P, Rianthavorn P. Longitudinal growth patterns and final height in childhood-onset systemic lupus erythematosus. Eur J Pediatr (2021) 180(5):1431&#x2013;41. doi: 10.1007/s00431-020-03910-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-020-03910-2</ArticleId><ArticleId IdType="pubmed">33389070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha A, Bagga A. Pulse steroid therapy. Indian J Pediatr (2008) 75(10):1057&#x2013;66. doi: 10.1007/s12098-008-0210-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12098-008-0210-7</ArticleId><ArticleId IdType="pubmed">19023530</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi&#x107; Z, Mici&#x107; D, Nikoli&#x107; J, Stojisavljevi&#x107; N, Soki&#x107; D, Jankovi&#x107; S, et al. . Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test. J Endocrinol Invest (1996) 19(1):30&#x2013;4. doi: 10.1007/BF03347855</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03347855</ArticleId><ArticleId IdType="pubmed">8851689</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol (1998) 25(10):1995&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pubmed">9779857</ArticleId></ArticleIdList></Reference><Reference><Citation>Koncak G, Tolunay O, Unal A, Celiloglu C, Celik U. Short-term side effects of pulse steroid treatment in children. J Coll Phys Surg Pak (2022) 32(2):262&#x2013;4. doi: 10.29271/jcpsp.2022.02.262</Citation><ArticleIdList><ArticleId IdType="doi">10.29271/jcpsp.2022.02.262</ArticleId><ArticleId IdType="pubmed">35108807</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther (2009) 11(4):R109. doi: 10.1186/ar2764</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2764</ArticleId><ArticleId IdType="pmc">PMC2745791</ArticleId><ArticleId IdType="pubmed">19604357</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Hoi A. Systemic lupus erythematosus: an update. Med J Aust (2017) 206(5):215&#x2013;20. doi: 10.5694/mja16.01229</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja16.01229</ArticleId><ArticleId IdType="pubmed">28301792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Garcia M, Espinosa G, Caminal L, Mitjavila F, Gonz&#xe1;lez-Le&#xf3;n R, et al. . First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med (2016) 3(1):e000153. doi: 10.1136/lupus-2016-000153</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000153</ArticleId><ArticleId IdType="pmc">PMC4985804</ArticleId><ArticleId IdType="pubmed">27547439</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, Medina JA, Ugarte A, Erdozain JG, et al. . Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res (Hoboken) (2018) 70(4):582&#x2013;91. doi: 10.1002/acr.23322</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23322</ArticleId><ArticleId IdType="pubmed">28704598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, Lazaro E, Iza A, Couzi L, et al. . Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev (2017) 16(8):826&#x2013;32. doi: 10.1016/j.autrev.2017.05.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.05.017</ArticleId><ArticleId IdType="pubmed">28564619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Ruiz-Estevez B, Lazaro E, Ruiz-Arruza I, Duffau P, Martin-Cascon M, et al. . Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmun Rev (2019) 18(9):102359. doi: 10.1016/j.autrev.2019.102359</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.102359</ArticleId><ArticleId IdType="pubmed">31323362</ArticleId></ArticleIdList></Reference><Reference><Citation>Sestak AL, F&#xfc;rnrohr BG, Harley JB, Merrill JT, Namjou B. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis (2011) 70(Suppl 1):i37&#x2013;43. doi: 10.1136/ard.2010.138057</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.138057</ArticleId><ArticleId IdType="pubmed">21339217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>